Research ExplorerPublicationsContemporary conditional cancer-specific survival rates in s...

Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis

Standard

Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis. / Panunzio, Andrea; Barletta, Francesco; Tappero, Stefano; Cano Garcia, Cristina; Piccinelli, Mattia; Incesu, Reha-Baris; Law, Kyle W; Tian, Zhe; Tafuri, Alessandro; Tilki, Derya; De Cobelli, Ottavio; Chun, Felix K H; Terrone, Carlo; Briganti, Alberto; Saad, Fred; Shariat, Shahrokh F; Bourdeau, Isabelle; Cerruto, Maria A; Antonelli, Alessandro; Karakiewicz, Pierre I.

In: J SURG ONCOL, Vol. 127, No. 4, 03.2023, p. 560-567.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Panunzio, A, Barletta, F, Tappero, S, Cano Garcia, C, Piccinelli, M, Incesu, R-B, Law, KW, Tian, Z, Tafuri, A, Tilki, D, De Cobelli, O, Chun, FKH, Terrone, C, Briganti, A, Saad, F, Shariat, SF, Bourdeau, I, Cerruto, MA, Antonelli, A & Karakiewicz, PI 2023, 'Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis', J SURG ONCOL, vol. 127, no. 4, pp. 560-567. https://doi.org/10.1002/jso.27161

APA

Panunzio, A., Barletta, F., Tappero, S., Cano Garcia, C., Piccinelli, M., Incesu, R-B., Law, K. W., Tian, Z., Tafuri, A., Tilki, D., De Cobelli, O., Chun, F. K. H., Terrone, C., Briganti, A., Saad, F., Shariat, S. F., Bourdeau, I., Cerruto, M. A., Antonelli, A., & Karakiewicz, P. I. (2023). Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis. J SURG ONCOL, 127(4), 560-567. https://doi.org/10.1002/jso.27161

Vancouver

Panunzio A, Barletta F, Tappero S, Cano Garcia C, Piccinelli M, Incesu R-B et al. Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis. J SURG ONCOL. 2023 Mar;127(4):560-567. https://doi.org/10.1002/jso.27161

Bibtex

@article{96cbf028630347bb95d16b291f1fed1a,
title = "Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis",
abstract = "BACKGROUND AND OBJECTIVES: We examined the effect of disease-free interval (DFI) duration on cancer-specific mortality (CSM)-free survival, otherwise known as the effect of conditional survival, in surgically treated adrenocortical carcinoma (ACC) patients.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2018), 867 ACC patients treated with adrenalectomy were identified. Conditional survival estimates at 5-years were assessed based on DFI duration and according to stage at presentation. Separate Cox regression models were fitted at baseline and according to DFI.RESULTS: Overall, 406 (47%), 285 (33%), and 176 (20%) patients were stage I-II, III and IV, respectively. In conditional survival analysis, providing a DFI of 24 months, 5-year CSM-free survival at initial diagnosis increased from 66% to 80% in stage I-II, from 35% to 66% in stage III, and from 14% to 36% in stage IV. In multivariable Cox regression models, stage III (hazard ratio [HR]: 2.38; p < 0.001) and IV (HR: 4.67; p < 0.001) independently predicted higher CSM, relative to stage I-II. The magnitude of this effect decreased over time, providing increasing DFI duration.CONCLUSIONS: In surgically treated ACC, survival probabilities increase with longer DFI duration. This improvement is more pronounced in stage III, followed by stages IV and I-II patients, in that order. Survival estimates accounting for DFI may prove valuable in patients counseling.",
keywords = "Humans, Adrenocortical Carcinoma/surgery, Survival Rate, Neoplasm Staging, Survival Analysis, Adrenal Cortex Neoplasms/surgery",
author = "Andrea Panunzio and Francesco Barletta and Stefano Tappero and {Cano Garcia}, Cristina and Mattia Piccinelli and Reha-Baris Incesu and Law, {Kyle W} and Zhe Tian and Alessandro Tafuri and Derya Tilki and {De Cobelli}, Ottavio and Chun, {Felix K H} and Carlo Terrone and Alberto Briganti and Fred Saad and Shariat, {Shahrokh F} and Isabelle Bourdeau and Cerruto, {Maria A} and Alessandro Antonelli and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2022 Wiley Periodicals LLC.",
year = "2023",
month = mar,
doi = "10.1002/jso.27161",
language = "English",
volume = "127",
pages = "560--567",
journal = "J SURG ONCOL",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis

AU - Panunzio, Andrea

AU - Barletta, Francesco

AU - Tappero, Stefano

AU - Cano Garcia, Cristina

AU - Piccinelli, Mattia

AU - Incesu, Reha-Baris

AU - Law, Kyle W

AU - Tian, Zhe

AU - Tafuri, Alessandro

AU - Tilki, Derya

AU - De Cobelli, Ottavio

AU - Chun, Felix K H

AU - Terrone, Carlo

AU - Briganti, Alberto

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Bourdeau, Isabelle

AU - Cerruto, Maria A

AU - Antonelli, Alessandro

AU - Karakiewicz, Pierre I

N1 - © 2022 Wiley Periodicals LLC.

PY - 2023/3

Y1 - 2023/3

N2 - BACKGROUND AND OBJECTIVES: We examined the effect of disease-free interval (DFI) duration on cancer-specific mortality (CSM)-free survival, otherwise known as the effect of conditional survival, in surgically treated adrenocortical carcinoma (ACC) patients.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2018), 867 ACC patients treated with adrenalectomy were identified. Conditional survival estimates at 5-years were assessed based on DFI duration and according to stage at presentation. Separate Cox regression models were fitted at baseline and according to DFI.RESULTS: Overall, 406 (47%), 285 (33%), and 176 (20%) patients were stage I-II, III and IV, respectively. In conditional survival analysis, providing a DFI of 24 months, 5-year CSM-free survival at initial diagnosis increased from 66% to 80% in stage I-II, from 35% to 66% in stage III, and from 14% to 36% in stage IV. In multivariable Cox regression models, stage III (hazard ratio [HR]: 2.38; p < 0.001) and IV (HR: 4.67; p < 0.001) independently predicted higher CSM, relative to stage I-II. The magnitude of this effect decreased over time, providing increasing DFI duration.CONCLUSIONS: In surgically treated ACC, survival probabilities increase with longer DFI duration. This improvement is more pronounced in stage III, followed by stages IV and I-II patients, in that order. Survival estimates accounting for DFI may prove valuable in patients counseling.

AB - BACKGROUND AND OBJECTIVES: We examined the effect of disease-free interval (DFI) duration on cancer-specific mortality (CSM)-free survival, otherwise known as the effect of conditional survival, in surgically treated adrenocortical carcinoma (ACC) patients.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2018), 867 ACC patients treated with adrenalectomy were identified. Conditional survival estimates at 5-years were assessed based on DFI duration and according to stage at presentation. Separate Cox regression models were fitted at baseline and according to DFI.RESULTS: Overall, 406 (47%), 285 (33%), and 176 (20%) patients were stage I-II, III and IV, respectively. In conditional survival analysis, providing a DFI of 24 months, 5-year CSM-free survival at initial diagnosis increased from 66% to 80% in stage I-II, from 35% to 66% in stage III, and from 14% to 36% in stage IV. In multivariable Cox regression models, stage III (hazard ratio [HR]: 2.38; p < 0.001) and IV (HR: 4.67; p < 0.001) independently predicted higher CSM, relative to stage I-II. The magnitude of this effect decreased over time, providing increasing DFI duration.CONCLUSIONS: In surgically treated ACC, survival probabilities increase with longer DFI duration. This improvement is more pronounced in stage III, followed by stages IV and I-II patients, in that order. Survival estimates accounting for DFI may prove valuable in patients counseling.

KW - Humans

KW - Adrenocortical Carcinoma/surgery

KW - Survival Rate

KW - Neoplasm Staging

KW - Survival Analysis

KW - Adrenal Cortex Neoplasms/surgery

U2 - 10.1002/jso.27161

DO - 10.1002/jso.27161

M3 - SCORING: Journal article

C2 - 36434748

VL - 127

SP - 560

EP - 567

JO - J SURG ONCOL

JF - J SURG ONCOL

SN - 0022-4790

IS - 4

ER -